JP2008530055A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008530055A5 JP2008530055A5 JP2007554578A JP2007554578A JP2008530055A5 JP 2008530055 A5 JP2008530055 A5 JP 2008530055A5 JP 2007554578 A JP2007554578 A JP 2007554578A JP 2007554578 A JP2007554578 A JP 2007554578A JP 2008530055 A5 JP2008530055 A5 JP 2008530055A5
- Authority
- JP
- Japan
- Prior art keywords
- polymer
- nitric oxide
- releasing
- release
- proton donor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 claims description 544
- 229920000642 polymer Polymers 0.000 claims description 173
- 238000011282 treatment Methods 0.000 claims description 45
- 239000000463 material Substances 0.000 claims description 38
- -1 aminochitosan Polymers 0.000 claims description 33
- 239000003094 microcapsule Substances 0.000 claims description 33
- 239000000386 donor Substances 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 25
- 239000012876 carrier material Substances 0.000 claims description 22
- 208000033808 peripheral neuropathy Diseases 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 201000001119 neuropathy Diseases 0.000 claims description 19
- 230000007823 neuropathy Effects 0.000 claims description 19
- 229920002678 cellulose Polymers 0.000 claims description 17
- 239000001913 cellulose Substances 0.000 claims description 17
- 229920002635 polyurethane Polymers 0.000 claims description 17
- 239000004814 polyurethane Substances 0.000 claims description 17
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 16
- 229920000742 Cotton Polymers 0.000 claims description 15
- 229920002873 Polyethylenimine Polymers 0.000 claims description 15
- 239000004793 Polystyrene Substances 0.000 claims description 15
- 239000004816 latex Substances 0.000 claims description 15
- 229920000126 latex Polymers 0.000 claims description 15
- 229920002223 polystyrene Polymers 0.000 claims description 15
- 230000004913 activation Effects 0.000 claims description 14
- 235000010980 cellulose Nutrition 0.000 claims description 14
- 239000004005 microsphere Substances 0.000 claims description 14
- 239000002105 nanoparticle Substances 0.000 claims description 14
- 238000009987 spinning Methods 0.000 claims description 14
- 239000004698 Polyethylene Substances 0.000 claims description 13
- 229920002472 Starch Polymers 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 13
- 229920000573 polyethylene Polymers 0.000 claims description 13
- 239000008107 starch Substances 0.000 claims description 13
- 235000019698 starch Nutrition 0.000 claims description 13
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 108010010803 Gelatin Proteins 0.000 claims description 11
- 239000004952 Polyamide Substances 0.000 claims description 11
- 239000004721 Polyphenylene oxide Substances 0.000 claims description 11
- 239000004743 Polypropylene Substances 0.000 claims description 11
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 11
- 229920002988 biodegradable polymer Polymers 0.000 claims description 11
- 239000004621 biodegradable polymer Substances 0.000 claims description 11
- 239000000499 gel Substances 0.000 claims description 11
- 239000008273 gelatin Substances 0.000 claims description 11
- 229920000159 gelatin Polymers 0.000 claims description 11
- 235000019322 gelatine Nutrition 0.000 claims description 11
- 235000011852 gelatine desserts Nutrition 0.000 claims description 11
- 239000005014 poly(hydroxyalkanoate) Substances 0.000 claims description 11
- 229920002239 polyacrylonitrile Polymers 0.000 claims description 11
- 229920002647 polyamide Polymers 0.000 claims description 11
- 229920001610 polycaprolactone Polymers 0.000 claims description 11
- 239000004632 polycaprolactone Substances 0.000 claims description 11
- 229920000515 polycarbonate Polymers 0.000 claims description 11
- 239000004417 polycarbonate Substances 0.000 claims description 11
- 229920000728 polyester Polymers 0.000 claims description 11
- 229920000570 polyether Polymers 0.000 claims description 11
- 229920000903 polyhydroxyalkanoate Polymers 0.000 claims description 11
- 229920001155 polypropylene Polymers 0.000 claims description 11
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 11
- 239000011118 polyvinyl acetate Substances 0.000 claims description 11
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 11
- 230000002265 prevention Effects 0.000 claims description 11
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- MUMXDRRTIYLYMY-YJKCNMNRSA-N (Z)-[dodecyl-[6-(dodecylazaniumyl)hexyl]amino]-oxido-oxidoiminoazanium Chemical group CCCCCCCCCCCC[NH2+]CCCCCCN(CCCCCCCCCCCC)[N+](\[O-])=N\[O-] MUMXDRRTIYLYMY-YJKCNMNRSA-N 0.000 claims description 10
- 239000002250 absorbent Substances 0.000 claims description 10
- 230000002745 absorbent Effects 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 239000002121 nanofiber Substances 0.000 claims description 10
- 238000011287 therapeutic dose Methods 0.000 claims description 10
- 229920002125 Sokalan® Polymers 0.000 claims description 9
- 231100000397 ulcer Toxicity 0.000 claims description 9
- 208000025865 Ulcer Diseases 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 238000001523 electrospinning Methods 0.000 claims description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 6
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 6
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 6
- 150000001768 cations Chemical class 0.000 claims description 6
- 239000006260 foam Substances 0.000 claims description 6
- 239000007789 gas Substances 0.000 claims description 6
- 229910052709 silver Inorganic materials 0.000 claims description 6
- 239000004332 silver Substances 0.000 claims description 6
- 229920001661 Chitosan Polymers 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 5
- 239000012528 membrane Substances 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 4
- AMQJEAYHLZJPGS-UHFFFAOYSA-N N-Pentanol Chemical compound CCCCCO AMQJEAYHLZJPGS-UHFFFAOYSA-N 0.000 claims description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 4
- 238000000578 dry spinning Methods 0.000 claims description 4
- 238000001891 gel spinning Methods 0.000 claims description 4
- 150000004676 glycans Chemical class 0.000 claims description 4
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 claims description 4
- 239000000017 hydrogel Substances 0.000 claims description 4
- 238000002074 melt spinning Methods 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 229920000098 polyolefin Polymers 0.000 claims description 4
- 239000004094 surface-active agent Substances 0.000 claims description 4
- 238000002166 wet spinning Methods 0.000 claims description 4
- ICGQLNMKJVHCIR-UHFFFAOYSA-N 1,3,2-dioxazetidin-4-one Chemical compound O=C1ONO1 ICGQLNMKJVHCIR-UHFFFAOYSA-N 0.000 claims description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 3
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 3
- 239000003205 fragrance Substances 0.000 claims description 3
- 239000003446 ligand Substances 0.000 claims description 3
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 3
- 229920000333 poly(propyleneimine) Polymers 0.000 claims description 3
- 229920000058 polyacrylate Polymers 0.000 claims description 3
- 229920001184 polypeptide Polymers 0.000 claims description 3
- 150000004804 polysaccharides Polymers 0.000 claims description 3
- 239000004800 polyvinyl chloride Substances 0.000 claims description 3
- 229920000915 polyvinyl chloride Polymers 0.000 claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 239000000758 substrate Substances 0.000 claims description 3
- KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-naphthol Chemical compound C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 claims description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 125000002091 cationic group Chemical group 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 2
- 229930195729 fatty acid Natural products 0.000 claims description 2
- 239000000194 fatty acid Substances 0.000 claims description 2
- 150000004665 fatty acids Chemical class 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 229920005862 polyol Polymers 0.000 claims description 2
- 150000003077 polyols Chemical class 0.000 claims description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 2
- 125000000467 secondary amino group Chemical class [H]N([*:1])[*:2] 0.000 claims 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 claims 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims 1
- 150000001242 acetic acid derivatives Chemical class 0.000 claims 1
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 claims 1
- 239000003086 colorant Substances 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 235000021317 phosphate Nutrition 0.000 claims 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims 1
- 229920001282 polysaccharide Polymers 0.000 claims 1
- 239000005017 polysaccharide Substances 0.000 claims 1
- 150000003890 succinate salts Chemical class 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 20
- 201000010099 disease Diseases 0.000 description 17
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 15
- 239000011248 coating agent Substances 0.000 description 14
- 239000000835 fiber Substances 0.000 description 14
- 238000000576 coating method Methods 0.000 description 13
- 208000012902 Nervous system disease Diseases 0.000 description 12
- 208000025966 Neurological disease Diseases 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 230000035876 healing Effects 0.000 description 12
- 208000002193 Pain Diseases 0.000 description 10
- 206010056340 Diabetic ulcer Diseases 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 239000000203 mixture Substances 0.000 description 9
- 230000017531 blood circulation Effects 0.000 description 8
- 229920005594 polymer fiber Polymers 0.000 description 8
- 239000002861 polymer material Substances 0.000 description 8
- 206010012601 diabetes mellitus Diseases 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 150000003335 secondary amines Chemical class 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 5
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 5
- 206010052428 Wound Diseases 0.000 description 5
- 208000027418 Wounds and injury Diseases 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 210000004243 sweat Anatomy 0.000 description 5
- 230000000304 vasodilatating effect Effects 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102100028452 Nitric oxide synthase, endothelial Human genes 0.000 description 4
- 101710090055 Nitric oxide synthase, endothelial Proteins 0.000 description 4
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 4
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 4
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 4
- 230000001775 anti-pathogenic effect Effects 0.000 description 4
- 239000002246 antineoplastic agent Substances 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000004064 dysfunction Effects 0.000 description 4
- 230000002209 hydrophobic effect Effects 0.000 description 4
- 229920002959 polymer blend Polymers 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010047139 Vasoconstriction Diseases 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 229920001477 hydrophilic polymer Polymers 0.000 description 3
- 239000012051 hydrophobic carrier Substances 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 230000025033 vasoconstriction Effects 0.000 description 3
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 206010061666 Autonomic neuropathy Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- 206010034620 Peripheral sensory neuropathy Diseases 0.000 description 2
- 206010072170 Skin wound Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 230000003143 atherosclerotic effect Effects 0.000 description 2
- 238000009739 binding Methods 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 210000003414 extremity Anatomy 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229920001600 hydrophobic polymer Polymers 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- 201000005572 sensory peripheral neuropathy Diseases 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 210000003371 toe Anatomy 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- 108010053754 Aldehyde reductase Proteins 0.000 description 1
- 102100027265 Aldo-keto reductase family 1 member B1 Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010024229 Leprosy Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- XYMWUVQSPLHQGD-UHFFFAOYSA-N OC=1N[N+](=CC=1)[O-] Chemical group OC=1N[N+](=CC=1)[O-] XYMWUVQSPLHQGD-UHFFFAOYSA-N 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
- 208000004210 Pressure Ulcer Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000007981 Reye syndrome Diseases 0.000 description 1
- 150000004007 S-nitroso compounds Chemical class 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 208000000558 Varicose Ulcer Diseases 0.000 description 1
- HCKBXQRQAZGCCK-UHFFFAOYSA-N [O-][N+]([O-])=N.C=CC1=CC=CC=C1C=C Chemical class [O-][N+]([O-])=N.C=CC1=CC=CC=C1C=C HCKBXQRQAZGCCK-UHFFFAOYSA-N 0.000 description 1
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 238000004026 adhesive bonding Methods 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001323 aldoses Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000702 anti-platelet effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229920005601 base polymer Polymers 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000000476 body water Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229920002313 fluoropolymer Polymers 0.000 description 1
- 239000004811 fluoropolymer Substances 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000000852 hydrogen donor Substances 0.000 description 1
- 239000012052 hydrophilic carrier Substances 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000000944 neurotransmitter response Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 239000002840 nitric oxide donor Substances 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229960005489 paracetamol Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 230000010118 platelet activation Effects 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 239000003505 polymerization initiator Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000002476 tumorcidal effect Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000003639 vasoconstrictive effect Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229920003176 water-insoluble polymer Polymers 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05002935.4 | 2005-02-11 | ||
| EP05002935A EP1690558A1 (en) | 2005-02-11 | 2005-02-11 | Device for treatment of diabetic disorders |
| US65276005P | 2005-02-14 | 2005-02-14 | |
| US60/652,760 | 2005-02-14 | ||
| EP05018269.0 | 2005-08-23 | ||
| EP05018269A EP1757278A1 (en) | 2005-08-23 | 2005-08-23 | Device, system, and method comprising microencapsulated liquid for release of nitric oxide from a polymer |
| PCT/EP2006/050891 WO2006084912A1 (en) | 2005-02-11 | 2006-02-13 | Device method, and use for treatment of neuropathy involving nitric oxide |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012224096A Division JP2013047241A (ja) | 2005-02-11 | 2012-10-09 | 酸化窒素による神経障害の治療デバイス、方法および使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008530055A JP2008530055A (ja) | 2008-08-07 |
| JP2008530055A5 true JP2008530055A5 (https=) | 2012-12-20 |
| JP5175107B2 JP5175107B2 (ja) | 2013-04-03 |
Family
ID=39188888
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007554578A Expired - Lifetime JP5175107B2 (ja) | 2005-02-11 | 2006-02-13 | 酸化窒素による神経障害の治療デバイス、方法および使用 |
| JP2012224096A Pending JP2013047241A (ja) | 2005-02-11 | 2012-10-09 | 酸化窒素による神経障害の治療デバイス、方法および使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012224096A Pending JP2013047241A (ja) | 2005-02-11 | 2012-10-09 | 酸化窒素による神経障害の治療デバイス、方法および使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US8241650B2 (https=) |
| EP (2) | EP2119459A1 (https=) |
| JP (2) | JP5175107B2 (https=) |
| KR (1) | KR20070105331A (https=) |
| BR (1) | BRPI0606834A2 (https=) |
| CA (1) | CA2594407C (https=) |
| DE (1) | DE602006007808D1 (https=) |
| DK (1) | DK1846058T3 (https=) |
| ES (1) | ES2329930T3 (https=) |
| MX (1) | MX2007009690A (https=) |
| PL (1) | PL1846058T3 (https=) |
| WO (1) | WO2006084912A1 (https=) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4738352B2 (ja) | 2004-02-09 | 2011-08-03 | アミュレット ファーマシューティカルズ インコーポレイティッド | 一酸化窒素放出ポリマー |
| KR20070105331A (ko) * | 2005-02-11 | 2007-10-30 | 노랩스 에이비 | 일산화질소를 포함하는 신경병증의 치료 장치, 방법 및용도 |
| DE602006006432D1 (de) | 2005-03-24 | 2009-06-04 | Nolabs Ab | Kosmetische behandlung mit stickoxid, vorrichtung zur durchführung dieser behandlung und herstellungsverfahren dafür |
| ES2731298T3 (es) | 2005-05-27 | 2019-11-14 | Univ North Carolina Chapel Hill | Partículas de liberación de óxido nítrico para agentes terapéuticos de óxido nítrico y aplicaciones biomédicas |
| US8642093B2 (en) | 2007-10-30 | 2014-02-04 | The Invention Science Fund I, Llc | Methods and systems for use of photolyzable nitric oxide donors |
| US8221690B2 (en) | 2007-10-30 | 2012-07-17 | The Invention Science Fund I, Llc | Systems and devices that utilize photolyzable nitric oxide donors |
| US8877508B2 (en) | 2007-10-30 | 2014-11-04 | The Invention Science Fund I, Llc | Devices and systems that deliver nitric oxide |
| US8349262B2 (en) | 2007-10-30 | 2013-01-08 | The Invention Science Fund I, Llc | Nitric oxide permeable housings |
| US8980332B2 (en) | 2007-10-30 | 2015-03-17 | The Invention Science Fund I, Llc | Methods and systems for use of photolyzable nitric oxide donors |
| US10080823B2 (en) | 2007-10-30 | 2018-09-25 | Gearbox Llc | Substrates for nitric oxide releasing devices |
| US20100069887A1 (en) * | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Multiple chamber ex vivo adjustable-release final dosage form |
| US20100069821A1 (en) * | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Ex vivo modifiable medicament release-sites final dosage form |
| US20100068256A1 (en) | 2008-09-16 | 2010-03-18 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Ex vivo modifiable medicament release-substance |
| GB0821345D0 (en) | 2008-11-21 | 2008-12-31 | P Q Silicas Uk Ltd | Composition and dressing with nitric oxide |
| CA2771389C (en) | 2009-08-21 | 2019-04-09 | Novan, Inc. | Wound dressings, methods of using the same and methods of forming the same |
| WO2011022652A1 (en) | 2009-08-21 | 2011-02-24 | Novan, Inc. | Topical gels |
| CA2777066C (en) * | 2009-10-14 | 2020-02-18 | TheraVasc, LLC | Pharmaceutical formulations of nitrite and uses thereof |
| US8591876B2 (en) | 2010-12-15 | 2013-11-26 | Novan, Inc. | Methods of decreasing sebum production in the skin |
| WO2012118829A2 (en) | 2011-02-28 | 2012-09-07 | Novan, Inc. | Tertiary s-nitrosothiol-modified nitricoxide-releasing xerogels and methods of using the same |
| CA2835320A1 (en) | 2011-05-09 | 2012-11-15 | Topical Therapeutic Agent (Tta) Ltd. | Nitric oxide-sequestering topical formulations |
| ES2804263T3 (es) | 2011-07-05 | 2021-02-05 | Novan Inc | Composiciones tópicas |
| WO2013006613A1 (en) | 2011-07-05 | 2013-01-10 | Novan, Inc. | Methods of manufacturing topical compositions and apparatus for same |
| AU2013232576B2 (en) | 2012-03-14 | 2016-09-01 | Ligand Pharmaceuticals Incorporated | Nitric oxide releasing pharmaceutical compositions |
| US10010445B2 (en) | 2013-01-23 | 2018-07-03 | Jonathan Isserow | Treatment device using nanotechnology |
| US9636521B2 (en) | 2013-07-12 | 2017-05-02 | Jonathan Isserow | Heat and light treatment device using nanotechnology |
| US9675817B2 (en) | 2013-01-23 | 2017-06-13 | Jonathan Isserow | Heating device using exothermic chemical reaction |
| US10583037B2 (en) | 2013-01-23 | 2020-03-10 | Transqtronics, Llc. | Heating device using exothermic chemical reaction |
| US9855211B2 (en) | 2013-02-28 | 2018-01-02 | Novan, Inc. | Topical compositions and methods of using the same |
| KR101743124B1 (ko) | 2013-03-07 | 2017-06-02 | 주식회사 아이센스 | 일산화질소를 저장, 전달 할 수 있는 나노섬유의 제조방법 및 이에 의하여 제조된 일산화질소를 저장, 전달 할 수 있는 나노섬유 |
| KR102321169B1 (ko) | 2013-08-08 | 2021-11-02 | 노반, 인크. | 국소 조성물 및 그의 사용 방법 |
| KR101555523B1 (ko) | 2014-02-28 | 2015-09-25 | 부산대학교 산학협력단 | 산화질소 방출성 상처치료 필름 및 이의 제조방법 |
| USD747085S1 (en) | 2014-06-06 | 2016-01-12 | Sharone Piontkowski | Insole |
| USD746568S1 (en) | 2014-06-06 | 2016-01-05 | Sharone Piontkowski | Insole pads |
| US10322082B2 (en) | 2014-07-11 | 2019-06-18 | Novan, Inc. | Topical antiviral compositions and methods of using the same |
| CN106659675B (zh) | 2014-07-11 | 2023-07-04 | 诺万公司 | 局部抗病毒组合物和其使用方法 |
| WO2016010988A1 (en) | 2014-07-14 | 2016-01-21 | Novan, Inc. | Nitric oxide releasing nail coating compositions, nitric oxide releasing nail coatings, and methods of using the same |
| CA2919733A1 (en) | 2014-08-08 | 2016-02-08 | Novan, Inc. | Topical compositions and methods of using the same |
| WO2016025550A1 (en) * | 2014-08-14 | 2016-02-18 | Rohm And Haas Company | Polymer with releasable gas |
| US10849864B2 (en) | 2015-07-28 | 2020-12-01 | Novan, Inc. | Combinations and methods for the treatment and/or prevention of fungal infections |
| USD810301S1 (en) | 2016-02-14 | 2018-02-13 | Laina Gossman | Pair of midfoot insoles |
| EP3423100A4 (en) | 2016-03-02 | 2019-10-16 | Novan, Inc. | COMPOSITIONS FOR THE TREATMENT OF INFLAMMATION AND METHOD FOR THE TREATMENT THEREOF |
| CN109310630A (zh) | 2016-04-13 | 2019-02-05 | 诺万公司 | 用于治疗感染的组合物、系统、试剂盒和方法 |
| KR101888763B1 (ko) * | 2016-05-13 | 2018-09-20 | 광운대학교 산학협력단 | 일산화질소 저장 및 전달을 위한 나노섬유 |
| EP3570927A4 (en) * | 2017-01-21 | 2020-12-23 | Biocrede Inc. | MEDICAL PRODUCTS AND METHODS FOR THE CONTROLLED RELEASE OF NITROGEN OXIDE |
| US11534382B2 (en) | 2017-06-19 | 2022-12-27 | Novan, Inc. | Topical compositions and methods of using the same |
| KR102557290B1 (ko) * | 2017-11-16 | 2023-07-20 | 기초과학연구원 | 일산화질소 방출성 고분자, 이를 포함하는 일산화질소 방출성 나노 구조체, 및 이를 이용한 일산화질소 전달 방법 |
| US11285171B2 (en) | 2018-03-01 | 2022-03-29 | Novan, Inc. | Nitric oxide releasing suppositories and methods of use thereof |
| CN119345461A (zh) * | 2024-09-20 | 2025-01-24 | 上海市第六人民医院 | 一种负载dnsp-11多肽peg微球的聚己内酯神经支架及其制备方法 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3754368A (en) * | 1969-11-04 | 1973-08-28 | Moore Perk Corp | Sterile packaging method |
| US4182827A (en) * | 1978-08-31 | 1980-01-08 | Union Carbide Corporation | Polyurethane hydrogels having enhanced wetting rates |
| US5814666A (en) | 1992-04-13 | 1998-09-29 | The United States As Represented By The Department Of Health And Human Services | Encapsulated and non-encapsulated nitric oxide generators used as antimicrobial agents |
| US5405919A (en) | 1992-08-24 | 1995-04-11 | The United States Of America As Represented By The Secretary Of Health And Human Services | Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions and methods of treating biological disorders |
| US5650447A (en) * | 1992-08-24 | 1997-07-22 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Nitric oxide-releasing polymers to treat restenosis and related disorders |
| US5632981A (en) * | 1992-08-24 | 1997-05-27 | The United States Of America As Represented By The Department Of Health And Human Services | Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same |
| US5691423A (en) | 1992-08-24 | 1997-11-25 | The United States Of America As Represented By The Department Of Health And Human Services | Polysaccharide-bound nitric oxide-nucleophile adducts |
| US5466465A (en) * | 1993-12-30 | 1995-11-14 | Harrogate Holdings, Limited | Transdermal drug delivery system |
| US6709681B2 (en) | 1995-02-17 | 2004-03-23 | Aberdeen University | Acidified nitrite as an antimicrobial agent |
| US5519020A (en) | 1994-10-28 | 1996-05-21 | The University Of Akron | Polymeric wound healing accelerators |
| US5714511A (en) * | 1995-07-31 | 1998-02-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs |
| US5770645A (en) | 1996-08-02 | 1998-06-23 | Duke University Medical Center | Polymers for delivering nitric oxide in vivo |
| US5958427A (en) | 1996-11-08 | 1999-09-28 | Salzman; Andrew L. | Nitric oxide donor compounds and pharmaceutical compositions for pulmonary hypertension and other indications |
| SE512663C2 (sv) * | 1997-10-23 | 2000-04-17 | Biogram Ab | Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer |
| US6818018B1 (en) * | 1998-08-14 | 2004-11-16 | Incept Llc | In situ polymerizable hydrogels |
| US20040043068A1 (en) | 1998-09-29 | 2004-03-04 | Eugene Tedeschi | Uses for medical devices having a lubricious, nitric oxide-releasing coating |
| US6382526B1 (en) | 1998-10-01 | 2002-05-07 | The University Of Akron | Process and apparatus for the production of nanofibers |
| WO2000049993A2 (en) | 1999-02-24 | 2000-08-31 | Nitromed, Inc. | Nitrosated and nitrosylated steroids for the treatment of cardiovascular diseases and disorders |
| GB2354441A (en) | 1999-08-06 | 2001-03-28 | Mccormack Ltd | Composition for treating dentine hypersensitivity |
| US6737447B1 (en) | 1999-10-08 | 2004-05-18 | The University Of Akron | Nitric oxide-modified linear poly(ethylenimine) fibers and uses thereof |
| US6627301B2 (en) | 2000-03-28 | 2003-09-30 | Showa Denko Kabushiki Kaisha | Magnetic recording medium |
| WO2001085013A2 (en) | 2000-05-09 | 2001-11-15 | Nitromed, Inc. | Infrared thermography and methods of use |
| HUP0002628A2 (en) * | 2000-07-14 | 2002-06-29 | Keri Pharma Kft | Pharmaceutical combinations for treating diabetes |
| US6780849B2 (en) * | 2000-12-21 | 2004-08-24 | Scimed Life Systems, Inc. | Lipid-based nitric oxide donors |
| US20040009238A1 (en) * | 2002-07-09 | 2004-01-15 | Chris Miller | Exogenenous nitric oxide gas (gNO) therapy in wound healing |
| US6706274B2 (en) * | 2001-01-18 | 2004-03-16 | Scimed Life Systems, Inc. | Differential delivery of nitric oxide |
| DE10119680A1 (de) * | 2001-04-20 | 2002-11-14 | Boehringer Ingelheim Pharma | Verwendung von Radikalfänger-Verbindungen zur Behandlung und Verhinderung von no-abhängigen Störungen der Mikrozirkulation |
| US6520425B1 (en) | 2001-08-21 | 2003-02-18 | The University Of Akron | Process and apparatus for the production of nanofibers |
| US6703046B2 (en) * | 2001-10-04 | 2004-03-09 | Medtronic Ave Inc. | Highly cross-linked, extremely hydrophobic nitric oxide-releasing polymers and methods for their manufacture and use |
| AU2003205058A1 (en) * | 2002-01-08 | 2003-07-24 | Bernard Techologies, Inc. | Antimicrobial body covering articles |
| US6695992B2 (en) | 2002-01-22 | 2004-02-24 | The University Of Akron | Process and apparatus for the production of nanofibers |
| US20030219494A1 (en) | 2002-03-20 | 2003-11-27 | Smith Maree Therese | Compositions and methods of using them |
| JP2005537223A (ja) | 2002-04-05 | 2005-12-08 | ニトロメッド，インク． | 酸化窒素供与体、組成物および使用法 |
| AU2003237128A1 (en) | 2002-05-03 | 2003-11-17 | Duke University | Carbon nanotubules for storage of nitric oxide |
| WO2004012659A2 (en) | 2002-08-01 | 2004-02-12 | Nitromed, Inc. | Nitrosated proton pump inhibitors, compositions and methods of use |
| EP1545798A4 (en) | 2002-08-02 | 2006-06-14 | Us Gov Health & Human Serv | NETWORKED NITROGEN OXIDE RELEASING POLYAMINE-COATED SUBSTRATES, THESE COMPOSITIONS AND MANUFACTURING PROCESSES DAF R |
| US7972137B2 (en) | 2003-06-30 | 2011-07-05 | Rosen Gerald M | Anti-microbial dental formulations for the prevention and treatment of oral mucosal disease |
| WO2005003032A1 (en) | 2003-07-03 | 2005-01-13 | The University Court Of The University Of St Andrews | Zeolites for delivery of nitric oxide |
| JP2007508121A (ja) | 2003-10-14 | 2007-04-05 | キューブ メディカル エーエス | 血管形成術用バルーン |
| GB0326047D0 (en) | 2003-11-07 | 2003-12-10 | Univ Sheffield | Substance |
| KR20070105331A (ko) * | 2005-02-11 | 2007-10-30 | 노랩스 에이비 | 일산화질소를 포함하는 신경병증의 치료 장치, 방법 및용도 |
-
2006
- 2006-02-13 KR KR1020077018436A patent/KR20070105331A/ko not_active Withdrawn
- 2006-02-13 DK DK06708229T patent/DK1846058T3/da active
- 2006-02-13 WO PCT/EP2006/050891 patent/WO2006084912A1/en not_active Ceased
- 2006-02-13 ES ES06708229T patent/ES2329930T3/es not_active Expired - Lifetime
- 2006-02-13 BR BRPI0606834-0A patent/BRPI0606834A2/pt not_active IP Right Cessation
- 2006-02-13 PL PL06708229T patent/PL1846058T3/pl unknown
- 2006-02-13 CA CA2594407A patent/CA2594407C/en not_active Expired - Lifetime
- 2006-02-13 EP EP09165415A patent/EP2119459A1/en not_active Ceased
- 2006-02-13 EP EP06708229A patent/EP1846058B1/en not_active Expired - Lifetime
- 2006-02-13 JP JP2007554578A patent/JP5175107B2/ja not_active Expired - Lifetime
- 2006-02-13 DE DE602006007808T patent/DE602006007808D1/de not_active Expired - Lifetime
- 2006-02-13 MX MX2007009690A patent/MX2007009690A/es active IP Right Grant
-
2007
- 2007-08-10 US US11/891,678 patent/US8241650B2/en active Active
-
2012
- 2012-10-09 JP JP2012224096A patent/JP2013047241A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5175107B2 (ja) | 酸化窒素による神経障害の治療デバイス、方法および使用 | |
| JP2008530055A5 (https=) | ||
| EP1861130B1 (en) | Device and method for treatment of dermatomycosis, and in particular onychomycosis | |
| CN101242815B (zh) | 用于从聚合物中释放一氧化氮的包含微胶囊化的质子给体的装置、系统、和方法 | |
| US9427605B2 (en) | Cosmetic treatment with nitric oxide, device for performing said treatment and manufacturing method therefor | |
| US20160106657A9 (en) | Cosmetic Treatment with Nitric Oxide, Device for Performing Said Treatment and Manufacturing Method Therefor | |
| JP2008530054A (ja) | 酸化窒素を用いた口腔内の疾患を治療するデバイスおよびその製造方法 | |
| JP2008542327A (ja) | 一酸化窒素が関与する、処置および予備処置装置、ならびにその製造方法 | |
| WO2006100155A1 (en) | Device for wound care, and manufacturing method thereof, involving the use of nitric oxide | |
| CN101115512A (zh) | 治疗皮肤病菌特别是甲癣的设备和方法 | |
| CN101115514A (zh) | 以氧化氮治疗神经病变的设备、方法及用途 | |
| WO2006084913A2 (en) | Device for treatment of rectal disorders, and manufacturing process for the same, involving nitric oxide |